Healthcare Equipment and Supplies
Company Overview of Second Sight Medical Products, Inc.
Second Sight Medical Products, Inc., a medical device company, develops, manufactures, and markets implantable prosthetic devices to restore functional vision to blind patients. The company provides Argus II system, an implantable neurostimulation device for the treatment of outer retinal degenerations, such as retinitis pigmentosa. It has operations in North America, Europe, and the Middle East. The company was formerly known as Second Sight LLC. Second Sight Medical Products, Inc. was founded in 1998 and is headquartered in Sylmar, California.
12744 San Fernando Road
Sylmar, CA 91342
Founded in 1998
Key Executives for Second Sight Medical Products, Inc.
Chief Financial Officer and Principal Accounting Officer
Compensation as of Fiscal Year 2014.
Second Sight Medical Products, Inc. Key Developments
Second Sight Announces First Commercial Implants of the Argus II Retinal Prosthesis System in the United States
Jan 29 14
Second Sight Medical Products, Inc. announced that the Argus II Retinal Prosthesis System was implanted in patients with Retinitis Pigmentosa (RP) in the U.S. for the first time since it was approved by the U.S. Food and Drug Administration (FDA) last year. The first commercial implants were performed at the University of Michigan's Kellogg Eye Center by Thiran Jayasundera, MD, FRCSC, and David N. Zacks, MD, PhD. Dr. Stanislao Rizzo, Director of the University Hospital Ophthalmic Department in Pisa, Italy, the surgeon that helped launch the Argus II commercially in Europe, observed the first surgery performed. Ultimate outcomes will not be known for some period of time until the patients go through a period of rehab to train them on using the Argus II. Kellogg Eye Center has been selected by Second Sight as a "Center of Excellence" for its cutting-edge approach to medicine and unparalleled commitment to patient care. It is one of 12 centers nationally that are currently accepting consultations for patients.
Second Sight Medical Products, Inc. Presents at 15th Annual SoCalBio Investor & Partnership Conference, Nov-06-2013 02:45 PM
Nov 3 13
Second Sight Medical Products, Inc. Presents at 15th Annual SoCalBio Investor & Partnership Conference, Nov-06-2013 02:45 PM. Venue: Omni Hotel, 251 South Olive Street, Los Angeles, CA 90012, United States. Speakers: Arup Roy, PhD, Director of Systems R&D Group.
Second Sight Medical Products's Argus(R) II Retinal Implant Now Available Also in the Netherlands
Jul 4 13
Second Sight Medical Products, Inc. announced that Argus II Bionic Eye is now also available in the Netherlands. Many patients suffering from Retinitis Pigmentosa have now the possibility to regain some functional vision with this treatment. In the Argus II Retinal Prosthesis System a mini camera mounted on sunglasses captures the scene. The images are first processed by a video processing unit; this data is then transmitted wirelessly to the implant that stimulates the remaining healthy cells of the retina, inducing pattern of lights that the brain interprets as shapes and movements. This technique allows blind people who suffer from the hereditary condition to distinguish light and contours again. Clinical results have demonstrated that Argus II is reliable over the long term and provides benefit to implanted patients followed up to 5 years. In daily life activities, profoundly blind Argus II users improved dramatically in their ability to conduct visual tasks and complement to other assistive means used by the blind. It may also enable other life style tasks generally considered impossible for the blind (for example reading). For all users, it means being connected to the visual world again, with all its associated advantages in terms of social interactions, and independence. The treatment has been commercially available till now in many hospitals worldwide, located in Germany, Italy, England, France, Switzerland, Saudi Arabia and the USA.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|